Eli Lilly Closes $3.8B AtaiBeckley Deal, ATAI Delisted
Eli Lilly completed its acquisition of AtaiBeckley on September 11, 2026, retiring ATAI shares from Nasdaq and folding a nine-asset psychedelic-treatment pipeline into one of the world's largest drugm
Eli Lilly Closes $3.8B AtaiBeckley Deal, ATAI Delisted
NEW YORK, September 14 —
AtaiBeckley Inc. (ATAI) surrendered its Nasdaq listing on September 11, 2026, when Eli Lilly completed an acquisition reported at up to $3.8 billion for a company that has never generated revenue. The timing matters: shareholders voted to approve the deal on September 8, three days before close, just as AtaiBeckley posted its first quarterly earnings beat in the available record.
- $3.8B deal value for a company with $0 revenue, $127M operating cash burn, and $233M cash on hand.
- Shareholders approved the merger September 8; Nasdaq delisted ATAI common stock when the acquisition closed September 11.
- Most recent quarter: first earnings beat in the four-quarter series available, a 17.9% positive surprise.
A Research Portfolio, Not a Business
AtaiBeckley, founded in 2018 and renamed from Atai Beckley N.V. in December 2025, developed rapid-acting treatments for mental health conditions where existing options are sparse. Its lead asset, BPL-003, is an intranasal formulation advancing through Phase 2 and Phase 3 trials for treatment-resistant depression and alcohol use disorder. The broader pipeline spans nine assets, including RL-007 for schizophrenia-associated cognitive impairment, EMP-01 (an R-enantiomer MDMA formulation for social anxiety disorder), and VLS-01, an oral DMT film. Lilly's purchase is a research portfolio play: no commercial revenue, no long-term debt, and $233 million in cash built entirely through capital raises, where a DCF valuation requires probability-weighting unproven clinical outcomes rather than discounting known cash flows.
Who Captured the Inflection
ATAI's earnings record before the deal is a useful frame: misses of 128.7% and 1,443.6% in the two preceding reported periods, a skipped quarter, and then a 17.9% positive surprise in the most recent one. The positive surprise arrived at the precise moment Lilly's offer was already locked in. Whether that price accounts for a pipeline finally turning in the right direction, or was negotiated before the trajectory shifted, shapes how one reads shareholder approval. Cathie Wood called it "well-deserved" for shareholders, per news coverage, a verdict that characterizes the price as fair rather than early to the inflection.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ATAI | $2.7B | n/a | +58.1% |
| GHRS | $1.9B | n/a | +107.5% |
| CMPS | $2.0B | n/a | +179.2% |
| HELP | $948M | n/a | +115.8% |
| IXHL | $39M | n/a | -79.5% |
| ABSI | $1.4B | n/a | +213.4% |
The Milestone Clock
Form 4 filings show that on the close date, Christian Angermayer disposed of approximately 55.76 million shares across three non-market transactions, Srinivas Rao reported 216,442 shares, Chief Accounting Officer Anne Nagengast Johnson 140,045 shares, and Chief Scientific Officer Glenn Frank Short 42,333 shares. All are merger mechanics, not discretionary selling. The operative question is now Lilly's: whether BPL-003 can reach Phase 3 readouts with major-pharma resources behind it, and whether the broader pipeline advances to key data that would eventually reveal whether $3.8 billion was a full price or a discount. Run the free AtaiBeckley Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Eli Lilly completed its acquisition of AtaiBeckley on September 11, 2026, retiring ATAI shares from Nasdaq and folding a nine-asset psychedelic-treatment pipeline into one of the world's largest drugmakers. The deal values a company that has never generated a dollar of revenue at up to $3.8 billion — and closed just after AtaiBeckley posted its first earnings beat in at least four quarters.